Inventor · disambiguated record
Stanley Wiegand
Also filed as: WIEGAND STANLEY · WIEGAND STANLEY J
23 granted patents·10 pending applications·862 citations·filing 1996–2021
97Inventor score
Top patents by PatentIndex Score
33 records- 0199US7306799B2Use of VEGF inhibitors for treatment of eye disordersREGENERON PHARMA·Filed 2005·Granted Dec 11, 2007·140 cites·11 claims
- 0299US7303747B2Use of VEGF inhibitors for treatment of eye disordersREGENERON PHARMA·Filed 2005·Granted Dec 4, 2007·112 cites·6 claims
- 0398US7531173B2Ophthalmic composition of a VEGF antagonistREGENERON PHARMA·Filed 2007·Granted May 12, 2009·109 cites·2 claims
- 0498US7521049B2Use of VEGF inhibitors for treatment of eye disordersREGENERON PHARMA·Filed 2007·Granted Apr 21, 2009·74 cites·15 claims
- 0598US7303746B2Methods of treating eye disorders with modified chimeric polypeptidesREGENERON PHARMA·Filed 2004·Granted Dec 4, 2007·117 cites·5 claims
- 0697US9795121B2Humanized C3 animalsREGENERON PHARMA·Filed 2015·Granted Oct 24, 2017·18 cites·23 claims
- 0797US9265827B2Anti-PDGFR-beta antibodies and uses thereofREGENERON PHARMA·Filed 2014·Granted Feb 23, 2016·87 cites·6 claims
- 0897US7303748B2Method of treating eye injury with local administration of a VEGF inhibitorREGENERON PHARMA·Filed 2006·Granted Dec 4, 2007·49 cites·10 claims
- 0996US7309483B2Method of treatment using Tie2 ligand2REGENERON PHARMA·Filed 2005·Granted Dec 18, 2007·32 cites·3 claims
- 1095US7378095B2Methods of treating type I diabetes by blocking VEGF-mediated activityREGENERON PHARMA·Filed 2005·Granted May 27, 2008·24 cites·5 claims
- 1192US9650444B2Anti-PDGFR-beta antibodies and uses thereofREGENERON PHARMA·Filed 2016·Granted May 16, 2017·12 cites·17 claims
- 1289US7052691B2Methods of treating diabetes by blocking VEGF-mediated activityREGENERON PHARMA·Filed 2004·Granted May 30, 2006·32 cites·13 claims
- 1387US10492477B2Humanized C5 animalsREGENERON PHARMA·Filed 2017·Granted Dec 3, 2019·2 cites·26 claims
- 1486US11178860B2Humanized C5 animalsREGENERON PHARMA·Filed 2019·Granted Nov 23, 2021·1 cites·20 claims
- 1585US7300654B2Method of treating corneal transplant rejection in high risk keratoplasty patientsREGENERON PHARMA·Filed 2005·Granted Nov 27, 2007·8 cites·4 claims
- 1682US7300653B2Method of treating corneal transplant rejectionREGENERON PHARMA·Filed 2004·Granted Nov 27, 2007·19 cites·8 claims
- 1777US2022132818A1Humanized c5 animalsREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 1871US10524458B2Humanized C3 animalsREGENERON PHARMA·Filed 2018·Granted Jan 7, 2020·0 cites·24 claims
- 1966US11071780B2Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumabREGENERON PHARMA·Filed 2018·Granted Jul 27, 2021·0 cites·9 claims
- 2064US6472178B1Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereofREGENERON PHARMA·Filed 1998·Granted Oct 29, 2002·13 cites·6 claims
- 2157US10023642B2Anti-PDGFR-beta antibodies and uses thereofREGENERON PHARMA·Filed 2017·Granted Jul 17, 2018·0 cites·4 claims
- 2256US7119066B2Modified ciliary neurotrophic factor (CNTF)REGENERON PHARMA·Filed 2002·Granted Oct 10, 2006·0 cites·2 claims
- 2352US2006123492A1Methods of identifying modulators of NMUR2-mediated activityWIEGAND STANLEY J·Filed 2006·Application pending·0 cites
- 2450US2002123462A1Modified ciliary neurotrophic factor, method of making and methods of use thereofFiled 2001·Application pending·0 cites
- 2549US2017080086A1Methods and formulations for treating vascular eye diseasesREGENERON PHARMA·Filed 2016·Application pending·0 cites
- 2648US2003040463A1TIE-2 ligands, methods of making and uses thereofFiled 2002·Application pending·0 cites
- 2747US6680291B1Modified ciliary neurotrophic factor, method of making and methods of use thereofREGENERON PHARMA·Filed 1999·Granted Jan 20, 2004·6 cites·6 claims
- 2847US2008181893A1Therapeutic methods for treating vascular eye disorders with DII4 antagonistsLOBOV IVAN B·Filed 2007·Application pending·0 cites
- 2946US2016144025A1Methods and formulations for treating vascular eye diseasesREGENERON PHARMA·Filed 2015·Application pending·0 cites
- 3044US2016120941A1Methods of using il-1 antagonists to treat alzheimer's diseaseREGENERON PHARMA·Filed 2014·Application pending·0 cites
- 3143US6410510B1Administration modified ciliary neurotrophic factorsREGENERON PHARMA·Filed 1996·Granted Jun 25, 2002·7 cites·2 claims
- 3242US2016152717A1Methods for treating dry eye disease by administering an il-6r antagonistREGENERON PHARMA·Filed 2015·Application pending·0 cites
- 3338US2006058224A1Methods of treating obesity with combination therapeuticsYANCOPOULOS GEORGE D·Filed 2005·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →